Silexion Therapeutics (NASDAQ:SLXN) Rating Lowered to Hold at Maxim Group

Silexion Therapeutics (NASDAQ:SLXN – Get Free Report) was downgraded by analysts at Maxim Group from a “strong-buy” rating to a “hold” rating in a research note issued on Wednesday,Zacks.com reports.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Silexion Therapeutics in a report on Monday, June 15th. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Silexion Therapeutics presently has an average rating of “Hold”.

Get Silexion Therapeutics alerts:

View Our Latest Research Report on SLXN

Silexion Therapeutics Stock Up 15.0%

NASDAQ:SLXN opened at $1.84 on Wednesday. The stock’s 50 day moving average price is $3.17 and its 200 day moving average price is $10.12. Silexion Therapeutics has a 52-week low of $1.50 and a 52-week high of $223.60. The company has a market capitalization of $772,800.00, a PE ratio of -0.02 and a beta of -0.26.

Silexion Therapeutics (NASDAQ:SLXN – Get Free Report) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($12.90) by $12.05. As a group, sell-side analysts anticipate that Silexion Therapeutics will post -45.5 EPS for the current fiscal year.

About Silexion Therapeutics

(Get Free Report)

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.

Read More

• Five stocks we like better than Silexion Therapeutics
• Microsoft Just Flipped the AI Spending Narrative Overnight
• Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
• Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
• Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes

Receive News & Ratings for Silexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.